Subscribe to our Newsletters !!
Anemones Sea have a striking beauty and the abilit
Today, we live in a world of advanced biotechnolog
A new COVID-19 variant, BA.3.2, informally called
Alembic Pharmaceutica
Potassium cyanide is infamous in the world for the
Tofu used to be associated with Asian cuisine, but
Dear Readers, Welcome to a fresh and forward-lo
The Hyderabad-based firm has settled litigation with Celgene, a wholly-owned subsidiary of Bristol Myers Squibb, Dr Reddy”s Laboratories said in a statement.
In settlement of all outstanding claims in the litigation, Celgene has agreed to provide the company with a permit to sell volume-limited amounts of generic lenalidomide capsules in america starting on a confidential date after March 2022 subject to regulatory approval, it added.
The agreed-upon proportions are confidential, Dr Reddy”s said.
The drug maker is already licensed to sell generic lenalidomide capsules in the US without volume limitation starting on January 31, 2026, Dr Reddy”s said.
“We are satisfied with the settlement agreement, and look forward to bringing a generic version of lenalidomide to market shortly subject to regulatory approval for the benefit of patients,” Dr Reddy”s Laboratories North America Generics CEO Marc Kikuchi said.
Revlimid, a trademark of Celgene, is used in the treatment of multiple myeloma and myelodysplastic syndromes. PTI MSS RVK
